Skip to main content
. Author manuscript; available in PMC: 2013 Jul 22.
Published in final edited form as: J Immunol. 2009 Aug 26;183(6):3661–3671. doi: 10.4049/jimmunol.0901218

Figure 2. Augmented [Ca2+]i responses and normal in vivo expansion by CD21/35−/− B cells.

Figure 2

A, BCR-induced [Ca2+]i responses by B220+ splenocytes, and peritoneal B-1b and B-1a cells from wild type (WT) and CD21/35−/− mice. F(ab')2 anti-IgM Ab (10 or 40 μg/ml) was added to the cells after 1 min (arrowhead) with relative [Ca2+]i concentrations were assessed by flow cytometry. Results represent those obtained in 2–4 experiments. B–E, In vivo expansion of Ag-specific spleen and peritoneal B cells 3 days following immunization. B, Representative flow cytometry analysis of TNP30-FITC-Ficoll-binding by splenic and peritoneal B220+ B cells from WT mice before and after immunization with TNP52-Ficoll. C, TNP30-FITC-Ficoll-binding B cell frequencies in WT mice immunized with TNP52-Ficoll, TNP4-Ficoll, TNP30-BSA, or PBS. D, Frequencies and numbers of B220+TNP30-FITC-Ficoll+ cells from WT, CD21/35−/−, and CD19−/− mice immunized with TNP52-Ficoll or PBS. C–D, Values represent means (±SEM) generated using 3–5 mice per group. Means significantly different from PBS control means are indicated by asterisks; *, p<0.05.